Bristol-Myers Squibb Company (BMY) - Total Liabilities
Based on the latest financial reports, Bristol-Myers Squibb Company (BMY) has total liabilities worth $66.37 Billion USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Bristol-Myers Squibb Company - Total Liabilities Trend (1987–2025)
This chart illustrates how Bristol-Myers Squibb Company's total liabilities have evolved over time, based on quarterly financial data. See BMY current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Bristol-Myers Squibb Company Competitors by Total Liabilities
The table below lists competitors of Bristol-Myers Squibb Company ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Safran SA
PA:SAF
|
France | €46.35 Billion |
|
China Merchants Bank Co Ltd
SHG:600036
|
China | CN¥11.36 Trillion |
|
Banco Bilbao Vizcaya Argentaria SA
MC:BBVA
|
Spain | €751.25 Billion |
|
PDD Holdings Inc.
NASDAQ:PDD
|
USA | $215.27 Billion |
|
Newmont Corporation
AU:NEM
|
Australia | AU$22.57 Billion |
|
Altria Group
NYSE:MO
|
USA | $38.47 Billion |
|
UNICREDIT S.P.A. ADR
F:CRIP
|
Germany | €833.36 Billion |
|
GlaxoSmithKline PLC ADR
NYSE:GSK
|
USA | $59.93 Billion |
Liability Composition Analysis (1987–2025)
This chart breaks down Bristol-Myers Squibb Company's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see BMY market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.77 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bristol-Myers Squibb Company's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bristol-Myers Squibb Company (1987–2025)
The table below shows the annual total liabilities of Bristol-Myers Squibb Company from 1987 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $71.53 Billion | -6.14% |
| 2024-12-31 | $76.22 Billion | +16.05% |
| 2023-12-31 | $65.67 Billion | -0.04% |
| 2022-12-31 | $65.70 Billion | -10.38% |
| 2021-12-31 | $73.31 Billion | -9.05% |
| 2020-12-31 | $80.60 Billion | +3.01% |
| 2019-12-31 | $78.25 Billion | +275.12% |
| 2018-12-31 | $20.86 Billion | -3.89% |
| 2017-12-31 | $21.70 Billion | +25.02% |
| 2016-12-31 | $17.36 Billion | +0.21% |
| 2015-12-31 | $17.32 Billion | -7.68% |
| 2014-12-31 | $18.77 Billion | -19.65% |
| 2013-12-31 | $23.36 Billion | +4.93% |
| 2012-12-31 | $22.26 Billion | +30.15% |
| 2011-12-31 | $17.10 Billion | +10.79% |
| 2010-12-31 | $15.44 Billion | -4.84% |
| 2009-12-31 | $16.22 Billion | -6.11% |
| 2008-12-31 | $17.28 Billion | +10.69% |
| 2007-12-31 | $15.61 Billion | +0.17% |
| 2006-12-31 | $15.58 Billion | -7.95% |
| 2005-12-31 | $16.93 Billion | -16.32% |
| 2004-12-31 | $20.23 Billion | +14.56% |
| 2003-12-31 | $17.66 Billion | +8.58% |
| 2002-12-31 | $16.27 Billion | -0.34% |
| 2001-12-31 | $16.32 Billion | +94.34% |
| 2000-12-31 | $8.40 Billion | -0.84% |
| 1999-12-31 | $8.47 Billion | -2.61% |
| 1998-12-31 | $8.70 Billion | +12.09% |
| 1997-12-31 | $7.76 Billion | -4.40% |
| 1996-12-31 | $8.12 Billion | +0.10% |
| 1995-12-31 | $8.11 Billion | +12.50% |
| 1994-12-31 | $7.21 Billion | +16.96% |
| 1993-12-31 | $6.16 Billion | +28.78% |
| 1992-12-31 | $4.78 Billion | +32.12% |
| 1991-12-31 | $3.62 Billion | -4.64% |
| 1990-12-31 | $3.80 Billion | +11.25% |
| 1989-12-31 | $3.41 Billion | +2.65% |
| 1988-12-31 | $3.33 Billion | +20.51% |
| 1987-12-31 | $2.76 Billion | -- |
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for… Read more